The tirzepatide difference: about a week earlier
Semaglutide has a half-life of about 7 days. Tirzepatide's is about 5 days. Applying the standard five half-lives rule, semaglutide is essentially cleared around 5 weeks after the last dose; tirzepatide around 25 days.
In practice that means Zepbound and Mounjaro users generally feel appetite returning about a week sooner than people coming off Ozempic or Wegovy. If you are comparing notes with a friend on the other molecule and your timelines will not line up, neither of you is doing it wrong. You can date your own curve with the washout calculator.
Drug still substantially active. Most people feel normal. Expect a 2 to 6 lb scale rise from fluid, not fat.
Roughly a quarter of the drug remains. Portions stop self-limiting and food noise starts flickering back.
The hard zone, arriving earlier than the semaglutide version. Appetite can rebound above your pre-drug baseline while your body burns several hundred fewer calories a day.
The regain window measured in SURMOUNT-4. Also when non-food improvements may drift back.
What SURMOUNT-4 actually found
This is the most direct evidence for tirzepatide specifically. After 36 weeks on the drug, participants either continued or switched to placebo. Over the following year:
- Those who continued kept losing weight
- Those who stopped regained about 14% of body weight
- 82% of stoppers gave back at least a quarter of what they had lost
Important context: this was a trial withdrawal, not a supported off-ramp. Nobody in the placebo arm received a structured maintenance plan. Cleveland Clinic real-world data across roughly 8,000 discontinuers found about 45% maintained or kept losing at one year. Both numbers are real; they describe different circumstances.
The extra wrinkle: you probably lost more
Tirzepatide adds a second hormone target (GIP) and produces larger average losses than semaglutide, up to roughly 22.5% of body weight in trials versus about 15%. That is the reason many people chose it, and it changes the exit math in two ways:
- A bigger result to protect. More weight lost means more at stake and, often, more emotional weight on the transition.
- A deeper metabolic gap. A larger loss means a larger drop in daily burn, between reduced body mass and metabolic adaptation. And if lean mass went with it, the furnace is smaller too.
None of that changes the levers, but it does raise the stakes on the two that protect body composition: protein and resistance training. More detail in the muscle loss guide.
Tapering from 15mg
The approved ladder is 2.5, 5, 7.5, 10, 12.5, 15mg weekly, and the label names 5, 10 and 15mg as maintenance doses. That matters: stepping down to a lower maintenance rung is a normal, label-anticipated conversation rather than an off-label request. Some clinicians also use extended intervals, which has emerging case-series support but no randomized trial. The microdosing chart lays out the ladder and grades each approach honestly.
What a taper changes is the height you fall from, not how fast the molecule clears. Stopping from 15mg delivers the whole appetite transition in one window; stepping down meets it in slices. Whether that improves long-term weight outcomes is still unproven, though most clinicians favor it. Specific schedules belong with your prescriber, and the wean-off guide has the questions to bring.
What to expect physically
- GI side effects resolve. Nausea, constipation and sulfur burps typically clear as stomach emptying returns to normal.
- Hunger and food noise return, weeks 2 to 5 on this molecule.
- Blood sugar changes if you were using it for type 2 diabetes. This needs prescriber supervision, not a plan from a website.
- Metabolic markers may drift as weight returns: blood pressure, cholesterol, liver values.
- No withdrawal syndrome. Tirzepatide does not produce physical dependence.
If you are on Mounjaro for type 2 diabetes
Mounjaro and Zepbound are the same molecule under two labels, but the clinical situation when you stop is genuinely different, and this deserves more than a footnote.
Tirzepatide lowers blood sugar substantially. When it clears, glucose control returns toward where it was before treatment, and that happens on the same 25-day timeline as everything else. For someone using it purely for weight, the consequence of stopping is appetite and weight. For someone using it for diabetes, the consequence is also a metabolic one that needs monitoring rather than observation.
What that changes in practice:
- Stopping is not a solo decision. This is true for everyone, but here it is a glucose-management question. Your prescriber may want to restart or adjust other diabetes medication as tirzepatide leaves, and that transition should be planned rather than discovered.
- Monitoring gets more important, not less. More frequent glucose checks through the washout weeks, and an HbA1c at a point your prescriber picks, will show what is actually happening rather than what you are guessing.
- Some improvements were never weight-mediated. Tirzepatide improves insulin sensitivity directly, not only through weight loss, so a portion of your glucose improvement is tied to the drug being present rather than to the pounds.
- The protein and strength work matters more here. Muscle is a major site of glucose disposal. Losing lean mass and then coming off the medication is a worse combination for blood sugar than either alone, which makes the muscle floor a metabolic intervention rather than a cosmetic one.
Insurance quirk worth knowing: Mounjaro is covered on a diabetes indication and Zepbound on a weight-management one. People are sometimes moved between them, or lose coverage for one while the other remains possible, even though the molecule is identical. If cost is what is ending your prescription, that is a specific question worth asking before accepting the outcome.
What holds the result
Identical to every other exit: a protein floor around 1.6g per kg of goal weight split across three meals, two or three short resistance sessions weekly, recalculated calorie targets, a smoothed weight trend watched closely enough to catch drift at 4 lbs, and a pre-built response for when the food noise returns. The full version is in how to not gain the weight back.